About Us
Technology & Pipeline
Governance
Investors
Media
Contact

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

October 20, 2021

Extraordinary General Meeting 2021

The Extraordinary General Meeting was held on Wednesday, 20 October 2021.

Documents

Protokoll extra bolagsstämma 2021 – Oasmia Pharmaceutical AB
Svenska 20 oktober, 2021
Minutes Extraordinary General Meeting 2021 – Oasmia Pharmaceutical AB
Swedish October 20, 2021
Press release – Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB
English October 20, 2021
Proxy Form – Oasmia Pharamceutical AB
English September 20, 2021
Postal voting form – Oasmia Pharmaceutical AB
English September 20, 2021
Press release – Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB
English September 20, 2021

Calendar

February 22, 2024
Year-end report January-December 2023
February 23, 2024
Year-end report 2023
April 22 - April 26, 2024
Annual Report publication

Corporate Governance

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer.

The company has a portfolio of projects with the potential of offering cancer patients with unmet medical needs new treatment alternatives. Vivesto has a track-record of developing drugs from the preclinical stage, through clinical development to regulatory approval.

Vivesto’s most advanced program Apealea® (paclitaxel micellar) has been granted market approval in the EU as a treatment for adult patients suffering from the first relapse of platinum sensitive epithelial ovarian cancer, or primary peritoneal cancer or fallopian tube cancer. Other clinical development programs include Cantrixil for late-stage ovarian cancer, and Docetaxel micellar, in development for advanced prostate cancer. Moreover, the company is developing Paccal Vet (paclitaxel micellar) for malignant melanoma and hemangiosarcoma in dogs. Vivesto has developed proprietary drug delivery technologies designed to improve solubility of various active pharmaceutical ingredients.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com